Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib

Volume: 24, Issue: 11, Pages: 2594 - 2604
Published: May 31, 2018
Abstract
Purpose: HER2 (or ERBB2) aberrations, including both amplification and mutations, have been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas. HER2 amplification is also an important mechanism for acquired resistance to EGFR tyrosine kinase inhibitors (TKI). However, due to limited preclinical studies and clinical trials, currently there is still no available standard of care for lung cancer patients with HER2...
Paper Details
Title
Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib
Published Date
May 31, 2018
Volume
24
Issue
11
Pages
2594 - 2604
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.